US2013089626A1PendingUtilityA1
Treating Cancer with ATR Inhibitors
Est. expirySep 30, 2031(~5.2 yrs left)· nominal 20-yr term from priority
A61N 2005/1098A61K 31/555A61K 31/7048A61P 43/00A61P 35/00A61P 1/18A61K 31/4965A61K 31/497A61K 45/06A61K 31/7068A61K 2121/00A61K 31/505A61K 31/506A61K 33/243A61K 33/24
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates to treating non-small cell lung cancer with an ATR inhibitor in combination with cisplatin or carboplatin, etoposide, and ionizing radiation.
Claims
exact text as granted — not AI-modified1 . A method of treating pancreatic cancer in a patient by administering to the patient an ATR inhibitor selected from
in combination with another cancer therapy selected from gemcitabine, radiation therapy, or both gemcitabine and radiation therapy together.
2 . The method of claim 1 , wherein the method increases the sensitivity of pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy.
3 . The method of claim 1 , wherein the cancer therapy is gemcitabine.
4 . The method of claim 1 , wherein the cancer therapy is radiation therapy.
5 . The method of claim 2 , wherein the pancreatic cancer cells are hypoxic pancreatic cancer cells.
6 . A method of inhibiting phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell comprising administering to a patient an ATR inhibitor selected from
in combination with gemcitabine and/or radiation.
7 . The method of claim 5 , wherein the cancer therapy is radiation therapy.
8 . The method of claim 5 , wherein the cancer therapy is gemcitabine.
9 . The method of claim 2 , wherein the cancer therapy comprises chemoradiation.
10 . The method of claim 9 wherein the chemotherapy is gemcitabine.
11 . A method of disrupting damage-induced cell cycle checkpoints by administering to a patient an ATR inhibitor selected from
in combination with radiation therapy.
12 . A method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering an ATR inhibitor selected from
in combination with radiation treatment.
13 . The method of claim 12 wherein the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.
14 . The method of claim 12 , wherein the pancreatic cancer cells are in a cancer patient.
15 - 16 . (canceled)
17 . A method of treating non-small cell lung cancer in a patient comprising administering to the patient a compound of formula 821 or 822:
in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation.
18 . The method of claim 17 , comprising administering to a patient a compound of formula 821 or 822 in combination with a cancer therapy selected from the group consisting of Cisplatin or Carboplatin, Etoposide, and ionizing radiation.
19 . The method of claim 18 , wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide.
20 . The method of claim 18 , wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide and ionizing radiation.
21 . The method of claim 18 , wherein the cancer therapy is ionizing radiation.
22 . The method according to claim 1 , wherein the ATR inhibitor is 822.
23 . The method according to claim 17 wherein the ATR inhibitor is 822.Join the waitlist — get patent alerts
Track US2013089626A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.